摘要
卵巢透明细胞癌(OCCC)是上皮性卵巢癌(EOC)相对罕见的一种组织学亚型,恶性程度高,对常规细胞毒性药物和铂类化疗药物敏感性低,预后差,因此找到针对OCCC治疗的生物学治疗靶点是临床迫切需要解决的难题。目前已知的OCCC治疗新分子靶点可大致分为4类:①AT丰富结合域1A(ARID1A)相关染色质重构差异;②受体酪氨酸激酶的下游通路;③抗氧化应激分子;④免疫调节功能异常。针对这些靶点已经研发了几种抑制剂,在体外实验和(或)体内实验中对OCCC细胞发挥抑制作用,然而在临床试验研究中未能显示出足够的有效性。
Ovarian clear cell carcinoma(OCCC)is a relatively rare histological subtype of epithelial ovarian cancer(EOC)with high level of malignant differentiation,low sensitivity to conventional cytotoxic drugs and platinum chemotherapeutic drugs,and poor prognosis.Therefore,it is an urgent clinical problem to find new therapeutic targets for OCCC therapy.The known new molecular targets for OCCC therapy can be divided into four categories:①AT-rich interactive domain 1A(ARID1A)-related chromatin remodeling errors;②downstream pathways of receptor tyrosine kinases;③antioxidant stress molecule;④immunomodulatory dysfunction.Several inhibitors have been identified.The in vitro and/or in vivo experiments have showed the inhibitory effects on OCCC cells.However,clinical trials did not show sufficient efficacy at present.
作者
杜媛媛
王安生
杨阳(审校)
DU Yuan-yuan;WANG An-sheng;YANG Yang(Department of Obstetrics and Gynecology,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《国际生殖健康／计划生育杂志》
CAS
2021年第4期348-352,共5页
Journal of International Reproductive Health/Family Planning
基金
国家自然科学基金(81702564)。
